Kumar Satyam’s Post

Advance Your Cancer Research with Central BioHub's Samples! 🔬 At #CentralBioHub, we understand the critical role that high-quality #biospecimens play in advancing #oncology research. With over 20,500 cancer samples available, our extensive inventory includes diverse matrices such as #plasma, serum, urine, buffy coat, PBMC, and #FFPE tissue samples. Central BioHub’s cancer samples are tested for critical biomarkers, including Cancer-antigen 125 (CA 125), Cancer-antigen 15-3 (CA 15-3), Cancer-antigen 19-9 (CA 19-9) and Carcinoembryonic antigen (CEA) These parameters are essential for monitoring cancer progression, validating diagnostic tools, and assessing treatment responses. We provide oncology researchers worldwide with a collection of biospecimens sourced from patients diagnosed with different types of cancer, such as Breast cancer, Lung cancer, Colorectal cancer and Prostate cancer. Here’s how #CentralBioHub can elevate your research experience: ·     Fast Delivery: Experience fast shipping within 5-10 days ·     Advanced Search Features: Our platform’s enhanced filtering options make it easy to find the exact biospecimens you need. Benefit from comprehensive clinical data and detailed histopathological data. ·     Expert Support: Our dedicated customer support team is here to assist you with any inquiries. For assistance, feel free to reach out at info@centralbiohub.com Explore cancer samples for your research on our website: https://lnkd.in/eb2fAd5H #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine #Cancer

Exciting news in the fight against myeloid cancers! Thermo Fisher Scientific has partnered with the National Cancer Institute (NCI) for the ground-breaking myeloMATCH precision medicine trial. This collaboration aims to revolutionize treatment for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Using Thermo Fisher Scientific's cutting-edge Ion Torrent Genexus System, researchers can now perform rapid genomic testing on patients' bone marrow and blood samples. This next-generation sequencing technology allows for quick identification of specific genetic biomarkers, enabling faster patient matching with appropriate clinical trials. The goal? To deliver comprehensive genomic results within days, dramatically speeding up patient enrolment in targeted sub-studies. This approach not only accelerates research but also increases access to precision oncology treatments for those battling these aggressive cancers. Let's celebrate this significant step towards more personalized and effective cancer care! https://lnkd.in/e-buK4JZ 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCare #PrecisionMedicine #CancerResearch #ThermofisherNCI

🔬✨ Unveiling the Power of ctDNA: Revolutionizing Cancer Care ✨🔬 Circulating tumor DNA (ctDNA) is reshaping the landscape of cancer care, offering a window into the intricacies of tumor biology like never before. Here's how: 🔍 Detecting Minimal Residual Disease (MRD): Post-surgery, ctDNA helps pinpoint lingering cancer cells, guiding tailored treatment decisions for optimal outcomes. 🔄 Monitoring Recurrence: With ctDNA, we can swiftly detect cancer recurrence during follow-up, enabling timely interventions and personalized care pathways. 💊 Predicting Treatment Response: By tracking changes in ctDNA levels, we gain invaluable insights into how patients respond to chemotherapy and immunotherapy, refining treatment strategies for better efficacy. 🧬 Biomarker Testing: When traditional tissue samples are scarce, ctDNA steps in, unlocking crucial genetic information (think KRAS, TMB) that shapes treatment choices and improves patient outcomes. ⚙️ Identifying Resistance Mutations: Uncovering mutations driving resistance to targeted therapies empowers us to adapt treatment regimens, ensuring continued effectiveness against cancer's evolving defenses. 💪🌟From guiding adjuvant therapies to tailoring surveillance protocols, ctDNA is a game-changer in oncology. While standardized guidelines are evolving, discussions with oncology teams can unlock its full potential, offering hope and progress in the fight against cancer. #ctDNA hashtag #CancerCare hashtag #Innovation hashtag #PrecisionMedicine hashtag #Oncology hashtag #ResearchAdvancements https://lnkd.in/dPvCG8dz https://lnkd.in/dXUE2-UZ https://lnkd.in/dQ3yZi2K

🚀 Latest publication from Pedro Fonte’s group on pioneering approaches in cancer treatment! 🚀 In our new paper, "Transforming Cancer Treatment: The Potential of Nanonutraceuticals," we explore the potential of nanonutraceuticals to overcome traditional chemotherapy challenges and bring targeted, more effective treatment options to cancer patients. 💊 Nanonutraceuticals: Offering enhanced solubility, stability, and targeted delivery to improve bioavailability and precision in treatment. 🎯 Targeted Therapy: Ligand-coupled nanocarriers enable nutraceuticals to directly reach cancer cells, minimizing off-target effects. ⚖️ Synergistic Treatment: Co-administration with chemotherapeutic drugs in nanocarriers amplifies therapeutic impact. 📑 From Research to Practice: Covering patents and clinical trials advancing nanonutraceuticals toward practical cancer therapies. Special thanks to my amazing co-authors for their commitment: @Girish Kumar, @Tarun Virmani, @Vaishnavi Chhabra, @Reshu Virmani, @Kamla Pathak, @Sayeed Akhtar, @Mulazim Hussain Asim, @Shumaila Arshad, @Farzana Siddique, and Pedro Fonte. 🔗 Read the full article here: https://lnkd.in/dCh-7Z6X #CancerResearch #Nanonutraceuticals #InnovativeTherapy #TargetedTreatment #Bioavailability #Nanotechnology

🚀 Don't Miss Out on Citeline's ESMO 2024 Recap Webinar: Unveiling Innovations and Trends in Cancer Care! 🗓️ Date: September 26, 2024 🕙 Time: 10am NYC | 3pm LDN 🌐 Location: Online Join Citeline's healthcare analysts as they break down the most impactful insights from this year's ESMO conference. Our expert panel will cover groundbreaking research, new treatment options, innovative technologies, and emerging trends shaping the future of oncology. ✨ What to Expect: 🔍 Overview of the latest research at ESMO 💊 Insight into cutting-edge cancer treatments 🧬 Discussion on innovative technologies transforming cancer care 📈 Summary of emerging oncology trends 📚 Key takeaways for healthcare professionals, researchers, and industry stakeholders 👥 Meet the Speakers: 🔹 Nkiru Ibeanu - Analyst I, Datamonitor Healthcare, Oncology | Citeline Expert in ovarian cancer, bladder cancer, and AML with a PhD in Ocular Pharmaceutics from UCL. 🔹 Anna Simmons - Pharmaceutical Analyst | Citeline Specialist in solid tumors, focusing on prostate cancer, breast cancers, and renal cell carcinoma with an M.Sc. in Biomedical Sciences from the University of Manchester. 👉 Register now to stay ahead of the curve and gain insights that will shape your strategy! https://lnkd.in/es39gUJt #Oncology #CancerCare #ESMO2024 #HealthcareInnovation #PharmaceuticalIndustry #MedicalResearch #Citeline #OncologyInsights

#RestlessLearners #HealthcareConsultant: Celebrating Dr. Lillian Siu's groundbreaking contributions to cancer research and patient care! 🌟 Dr. Siu's visionary leadership has significantly advanced the field of Precision Oncology and targeted therapies, pushing boundaries in medical oncology since 1998. "Molecular Profiling for Precision Cancer Therapies (2020)" sheds light on implementing comprehensive genomic profiling as a sustainable and cost-effective diagnostic tool, addressing uncertainties around patient benefits and clinical trial matching to targeted therapies. Worldwide initiatives like DRUP-like clinical trials (DLCTs) share the pragmatic core clinical trial design with broad inclusion criteria and a limited set of endpoints. We will analyse each implementation strategy of these trials, which aim to identify new predictive biomarkers for targeted treatments, provide new data and essential insights into molecular pathways involved in, e.g., resistance mechanisms and thereby potentially evolve and expand the personalized cancer treatment strategy. 💧 DRUP in the Netherlands: Sponsor The Netherlands Cancer Institute. The Drug Rediscovery Protocol (NCT02925234) 📣 MEGALiT in Sweden: Sponsor Uppsala University Hospital Information provided by Peter Nygren, Uppsala University Hospital (NCT04185831). 💡 IMPRESS in Norway: https://lnkd.in/gwiUpHgS 🎯 ProTarget in Denmark: ClinicalTrials.gov Identifier: NCT04341181. Secondary Identifying No: ML41742. EudraCT No: 2019-004771-40. Let's embrace continuous learning and development for better cancer treatments and patient outcomes. Are we there yet? 📚💡 #HealthcareInnovations #CancerResearch #PrecisionMedicine #PrecisionOncology #Oncologytrials #Rightpatient at the #righttime #Clinicaltrialmatching #Decisiondriven #dataanalytics

The landscape of cancer treatment is evolving rapidly, with immunotherapy at the forefront of potential therapeutic innovations. Among these, the role of gamma/delta (γδ) T cells as cellular vehicles for anti-tumour immunity presents a promising approach. Dr Chelsia Wang, Ms Pei Yu Lim, and Dr Andy Tan from the Immune Cell Manufacturing group at #BTI, shed light on the unique capabilities of γδ T cells in oncology, which straddle the line between innate and adaptive immunity. The cells’ unique positioning allows them to recognise a wide range of tumour antigens without the constraints of traditional antigen presentation mechanisms, opening the door to developing more universal cancer therapies. While the potential of γδ T cells is immense, the journey from laboratory to clinic is filled with both challenges and opportunities. The analysis in this paper underscores the need for a deeper understanding of the biological underpinnings of these cells, their tumour-targeting mechanisms, and how they interact within the complex tumour microenvironment. 💡Addressing these challenges head-on is essential for the advancement and optimisation of γδ T cell-based therapies, ensuring their success and applicability in real-world clinical settings. There is a greater need for an integrated approach combining advanced genetic engineering, innovative drug design, and comprehensive clinical trials, to unlock the full therapeutic potential of γδ T cells, thereby setting a new standard for cancer treatment. Link to the full article here: https://lnkd.in/gxUcE6Em Connect with us here and explore how we can enhance your research journey: https://lnkd.in/gRU66bP #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #GammaDeltaTcell #cancertreatment #immunotherapy

📅 This World Lung Cancer Day (August 1, 2024), it's important to highlight the advancements in precision oncology and genomic profiling that are improving patient care and survival rates. We welcome the release of London Agency's new whitepaper, in partnership with our member Thermo Fisher Scientific. This publication showcases how Rapid Genomic Profiling (RGP) is transforming outcomes for Australian patients by enabling faster treatment decisions and enhancing survival rates in lung cancer diagnosis, where treatments continue to advance! 🧬 With the rising number of lung cancer cases diagnosed each year, the adoption of precision oncology and genomic profiling empowers clinicians to identify unique mutations and alterations in each patient. This approach ensures the right drug is administered to the right patient at the right time. The swift identification of clinically actionable biomarkers is crucial, as delays in treatment initiation can be detrimental. Rapid turnaround time is therefore paramount in the fight against lung cancer. Investing in advanced technologies is essential for achieving equitable healthcare access for all, leading to positive clinical outcomes in patient care. Let's continue to support and advance these innovations for a healthier future. We look forward to meeting with Thermo Fisher today and learning more about their leading work in this field. 🌟 #WorldLungCancerDay #PrecisionOncology #GenomicProfiling #HealthcareInnovation #LungCancerAwareness Bansi Sanghvi, PhD Ronald Grasso Jeff Smith read the white paper here https://lnkd.in/gVN5wujt

Mark your calendars. We are excited to announce that we will be presenting the groundbreaking insights on DT-9045, our first-in-class Negative Allosteric Modulator of PAR2, during the AACR annual meeting 2024. 🗓 When: 7 April 2024 - from 1:30 PM – 5:00 PM PST 📍 Where: Poster section 27 – PO.ET09.05 – Novel Antitumor Agents 2 💡 Title: DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and #immunotherapy in #oncology models DT-9045 a true game-changer in #immunooncology with clear competitive pharmacological properties and unique therapeutic potential to unlock new possibilities in cancer treatment. Our latest preclinical data reveal solid perspectives for strategic clinical positioning, addressing high medical unmet needs across several tumor types. At Domain, we are pioneering new GPCR targets in immunosuppression aiming to increase the effectiveness of cancer immunotherapy. This novel, highly potent and selective PAR2 inhibitor reflects our unwavering dedication to precision research. We are eagerly looking forward to sharing these exciting findings with you! Let’s catch up in person, exchange ideas and forge connections that shape the future of cancer treatment! Our team of experts Marjorie Sidhoum Stephan Schann Nathalie Lenne Thibaut Brugat is ready to connect! For more details, check out the full press release in the comments below. Follow us for more updates on #drugdevelopment #precisionmedecine #cancerresearch American Association for Cancer Research

🌟 Exciting News in Cancer Treatment! 🌟 I am thrilled to share that the FDA has granted accelerated approval for TECELRA (afamitresgene autoleucel), marking a groundbreaking advancement in the treatment of unresectable or metastatic synovial sarcoma, a rare and challenging soft tissue cancer. This approval represents the first engineered cell therapy for solid tumors in the US, providing a much-needed option for patients who have exhausted traditional chemotherapy. 🔍 Key Highlights: Innovative Approach:  TECELRA utilizes genetically modified autologous T cells to target the MAGE-A4 antigen, harnessing the power of each patient’s own immune system to fight cancer. Promising Results:  Based on the Phase II SPEARHEAD-1 trial, TECELRA demonstrated a 43% overall response rate and a 4.5% complete response rate, showcasing its potential effectiveness. Hope for Patients:  With historically low five-year survival rates for synovial sarcoma patients, this approval signifies a critical development in expanding treatment options and improving patient outcomes. As we continue to explore the potential of cell therapies in oncology, this milestone not only brings renewed hope to patients but also paves the way for future innovations in cancer treatment. Let's celebrate this significant step forward in the fight against cancer! 💪🎗️ #CancerResearch #CellTherapy #FDAApproval #SynovialSarcoma #InnovativeMedicine #HealthcareInnovation #PatientCare #Oncology